Search

What can I expect?

Learning Objectives
To have a greater understanding of computational techniques as applied to haematological datasets,
To improve personal computational biology skillset, tailored to the project,
To further develop and widen your network of potential collaborators, both in terms of peer group and…

Novel basis for chemoresistance in AML: DNMT3A R882 mutations promote chemoresistance and residual disease through impaired DNA damage sensing

Jun 12 2015 Posted in Press releases

Although most acute myeloid leukemia (AML) patients initially respond to chemotherapy, the majority subsequently relapses and succumbs to refractory disease. Residual leukemic cells that survived chemotherapy may persist over time and later cause the disease to come back.

SWG Educational Activities

Recruitment trialsRecruitment is underway for the following trials:

Trial on precision hematology: Comprehensive Genomic Profiling and Next Generation Functional Drug Screening for Patients With Aggressive Haematological Malignancies (EXALT-2); ClinicalTrials.

Chairs and Members

Chairs
Chair ESLHO: Prof Dr J. J. M. van Dongen, USAL, Salamanca, Spain
Chair EuroFlow: Prof Dr J. J. M van Dongen, USAL, Salamanca, Spain
Chair EuroMRD: Prof Dr M.

Publications

Subconjunctival injection of mesenchymal stromal cells protects the cornea in an experimental model of GVHD. Martínez-Carrasco R, Sánchez-Abarca LI, Nieto-Gómez C, García EM, Sánchez-Guijo F, Argüeso P, Aijón J, Hernández-Galilea E, Velasco A. Ocul Surf. 2019 Jan 7.